Rapport Therapeutics Inc (NASDAQ: RAPP) on Friday, plunged -3.95% from the previous trading day, before settling in for the closing price of $10.12. Within the past 52 weeks, RAPP’s price has moved between $6.43 and $29.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 5.71%. With a float of $17.41 million, this company’s outstanding shares have now reached $36.58 million.
The firm has a total of 69 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Rapport Therapeutics Inc (RAPP) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Rapport Therapeutics Inc is 52.31%, while institutional ownership is 54.43%. The most recent insider transaction that took place on Mar 14 ’25, was worth 92,205. In this transaction Chief Scientific Officer of this company sold 8,500 shares at a rate of $10.85, taking the stock ownership to the 469,142 shares. Before that another transaction happened on Mar 14 ’25, when Company’s Officer proposed sale 25,500 for $10.02, making the entire transaction worth $255,510.
Rapport Therapeutics Inc (RAPP) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 5.71% per share during the next fiscal year.
Rapport Therapeutics Inc (NASDAQ: RAPP) Trading Performance Indicators
Rapport Therapeutics Inc (RAPP) is currently performing well based on its current performance indicators. A quick ratio of 35.34 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.14, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -4.26 in one year’s time.
Technical Analysis of Rapport Therapeutics Inc (RAPP)
Analysing the last 5-days average volume posted by the [Rapport Therapeutics Inc, RAPP], we can find that recorded value of 0.5 million was better than the volume posted last year of 0.21 million. As of the previous 9 days, the stock’s Stochastic %D was 57.01%. Additionally, its Average True Range was 1.32.
During the past 100 days, Rapport Therapeutics Inc’s (RAPP) raw stochastic average was set at 15.25%, which indicates a significant decrease from 66.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 191.74% in the past 14 days, which was higher than the 118.89% volatility it showed in the past 100 days.
Now, the first resistance to watch is $10.28. This is followed by the second major resistance level at $10.85. The third major resistance level sits at $11.43. If the price goes on to break the first support level at $9.13, it is likely to go to the next support level at $8.55. Now, if the price goes above the second support level, the third support stands at $7.98.
Rapport Therapeutics Inc (NASDAQ: RAPP) Key Stats
Market capitalization of the company is 354.75 million based on 36,496K outstanding shares. Right now, sales total 0 K and income totals -78,310 K. The company made 0 K in profit during its latest quarter, and -19,980 K in sales during its previous quarter.
